NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




GI Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Colon

Alliance A021502 - "RANDOMIZED TRIAL OF STANDARD CHEMOTHERAPY ALONE OR COMBINED WITH ATEZOLIZUMAB AS ADJUVANT THERAPY OF PATIENTS WITH STAGE III COLON CANCER WITH DEFICIENT DNA MISMATCH REPAIR"

CANCER TYPE: Colon
RESEARCH BASE: Alliance
NCT NUMBER: NCT02912559
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 03/06/2019 (18:20:20)

BRIEF DESCRIPTION

Colon, Stage III, deficient DNA mismatch repair, completely resected,  mFOLFOX6 +/- Atezolizumab.  DCP-001 Eligible






Liver

RTOG 1112 - "RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS STEREOTACTIC BODY RADIATION THERAPY FOLLOWED BY SORAFENIB IN HEPATOCELLULAR CARCINOMA"

CANCER TYPE: Liver
RESEARCH BASE: NRG
NCT NUMBER: NCT01730937
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

HCC, BCLC stage Intermediate (B) or advanced (C), Sorafenib alone VS. SBRT + Sorafenib.  DCP-001 Eligible






Pancreas

ECOG-ACRIN EA2142 - "Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas"

CANCER TYPE: Pancreas
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT02595424
Protocol Summary: VIEW SUMMARY
BRIEF DESCRIPTION

GI, locally advanced and unresectable, or metastatic, gastroenteropancreatic neuroendocrine non small cell carcinoma, Ki-67 20-100%, no brain mets.  Capecitabine and Temozolomide vs. Cisplatin (or Carboplatin) and Etoposide.









  © 2013-2019 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA